John Cijiang He, MD, PhD Email John Cijiang He
- PROFESSOR | Medicine, Nephrology
- PROFESSOR | Pharmacological Sciences
- Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Beth Israel
- Mount Sinai Morningside and Mount Sinai West
Dr. John Cijiang He got his MD from Shanghai Second medical University in China and PhD in Physiology at University of Paris VII in France. Then, he got his further research training as a visiting scientist at NIH in Maryland and The Picower Institute for Medical Research in New York. He completed his medical residency at SUNY down state and clinical nephrology fellowship at Mount Sinai Hospital in New York. Currently, he is a Professor of Medicine and Pharmacological Sciences at Icahn School of Medicine at Mount Sinai. He holds the title of Irene and Dr. Arthur Fishberg endowed chair of Nephrology. He is the chief of Nephrology at Mount Sinai Health System. He was the President of the New York Society of Nephrology and the President of Chinese American Society of Nephrology. He is the member of the American Society of Clinical Investigation. He is also a visiting professor at both Nanjing University and Shanghai Jiaotong University. He has been funded by multiple NIH and VA grants and has published more than 180 papers in the peer-reviewed scientific journals. His major research areas include glomerular cell biology, systems biology of kidney disease, and kidney fibrosis. His major clinical interest includes diabetic kidney disease, viral-induced kidney disease, and primary glomerular disease.
- Diabetic Kidney Disease
- Kidney Failure
Diabetes, HIV/AIDS, Kidney, Signal Transduction, Systems Biology
Multi-Disciplinary Training Area
Pharmacology and Therapeutics Discovery [PTD]
MD, Shanghai 2nd Medical School
MD, Shanghai Second Medical College
MS, University of Paris VII
, Rui-Jin Hospital, Shanghai 2nd Medical School
, Tenon Hospital
PhD, University of Paris VII
, Tenon Hospital
, SUNY Health Science Center
, SUNY Health Science Center
, The Mount Sinai Medical Center
Residency, Internal Medicine
S.U.N.Y., Health Science Center
Fellowship, Metabolic Diseases
National Institutes of Health
Fellowship, Renal Medicine
Mount Sinai Hospital
Podocyte Biology and Pathology
We are studying the signaling network that mediates podocyte differentiation and injury using both in vitro and in vivo models. We are studying the relationship between mechanical force, morphology, and chemical signals and their role in maintaining normal podocyte differentiation status. We are studying the mechanism of podocyte injury in diabetic kidney disease and HIV-associated nephropathy. We are studying how retinoic acid could repair podocyte injury through induction of differentiation and regeneration process.
Pathogenesis of diabetic kidney disease
We are studying the role of advanced glycation endproducts (AGE) and oxidative stress in podocyte injury and diabetic kidney disease. We are studying the role and the post-translational regulation (acetylation) of key transcription factors such as FOXO, NF-kB and Stat3 in mediating podocyte injury and diabetic kidney disease.
Role of HIPK2 in kidney fibrosis
We have identified that HIPK2 plays a key role in kidney fibrosis. We are studying the mechanism of HIPK2 in mediating kidney fibrosis and try to identify potential anti-fibrosis therapy by targeting HIPK2. Please visit the He Laboratory.
Using systems biology approach to study kidney disease
We are using systems biology approach to study cell signaling and gene transcription networks in kidney disease. We are studying the transcriptome, epigenome and proteome in injured podocytes and diseased kidney. We are using systems pharmacology approach to identify new drug targets or therapy for kidney disease.
Pathogenesis of HIV-Associated Nephropathy
We are studying the role of HIV viral protein in the development of HIV-associated nephropathy. The role and signaling pathways of HIV Nef have been studied in kidney podocytes. We are also investigating the mechanism of chronic HIV infection on the progression of other kidney diseases such as diabetic nephropathy and hypertensive kidney disease.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. He during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Chinese Medical Society of Nephrology
Scientific Advisory Board:
- Otsuka Pharmaceutical Co., Ltd.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.